BioSpace8h
Insilico Aces Second Mid-Stage IPF Trial in a Row
In a small Phase IIa trial, Insilico’s generative AI-designed idiopathic pulmonary fibrosis drug improved lung function and ...
BioSpace8h
Q3 Biotech Earnings Recap: Nkarta, Intellia, Cassava and more
BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.
BioSpace9h
23andMe Cuts Headcount by 40%, Drops Drug Discovery Work
In line with the restructuring initiative, 23andMe is looking for strategic opportunities for its pipeline assets, including ...
BioSpace10h
Neurogene Shares Tank After Adverse Event Linked to Early-Stage Rett Syndrome Gene Therapy
Analysts did not seem very concerned by the treatment-related serious adverse event, noting that NGN-401 was well-tolerated ...
BioSpace10h
Don’t Call It a Crossover, but Alentis Raises $181M Series D for ADC Work
CEO Roberto Iacone admitted in an interview that the market remains tough, even for a biotech in the red-hot ADC world. But ...
BioSpace23h
AstraZeneca Dodges China Questions While Raising 2024 Outlook With Strong Q3 Sales
The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the ...
BioSpace23h
Bayer Earnings ‘Not Pretty,’ CEO Bill Anderson Admits As He Urges Calm
Bayer reported a decline of 37% in earnings per share on Tuesday, which sent its stock down 12%. CEO Bill Anderson urged ...